Anbio Biotechnology (NNNN)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from NNNN's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Anbio Biotechnology's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $24M | $7M | $8M | $9M |
| Net income | $10M | $2M | $2M | $6M |
| Free cash flow | — | — | — | — |
| EPS (diluted) | $100,112.00 | $0.10 | $0.06 | $0.15 |
| Operating margin | 43.3% | 29.2% | 24.4% | 66.7% |
Where the revenue comes from
Revenue by regions, fiscal 2025. Every breakdown, year by year.
Superinvestors who own NNNN
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by Anbio Biotechnology's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when NNNN trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Anbio Biotechnology insiders buying the stock?
No open-market insider purchases of NNNN in the last 12 months, according to SEC Form 4 filings.
Companies like Anbio Biotechnology
All Healthcare stocks · Medical Instruments & Supplies stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.